Abstract:Nonischemic dilated cardiomyopathy is a common form of heart muscle disease in which genetic factors play a critical etiological role. In this regard, both rare disease‐causing mutations and common disease‐susceptible variants, in the Bcl‐2–associated athanogene 3 ( BAG3 ) gene have been reported, highlighting the critical role of BAG3 in cardiomyocytes and in the development of dilated cardiomyopathy. The phenotypic effects of the BAG3 mutations help investigators understand the structure and function of the BAG3 gene. Indeed, we report herein that all of the known pathogenic/likely pathogenic variants affect at least 1 of 3 protein functional domains, ie, the WW domain, the second IPV (Ile‐Pro‐Val) domain, or the BAG domain, whereas none of the missense nontruncating pathogenic/likely pathogenic variants affect the proline‐rich repeat (PXXP) domain. A common variant, p.Cys151Arg, associated with reduced susceptibility to dilated cardiomyopathy demonstrated a significant difference in allele frequencies among diverse human populations, suggesting evolutionary selective pressure. As BAG3 ‐related therapies for heart failure move from the laboratory to the clinic, the ability to provide precision medicine will depend in large part on having a thorough understanding of the potential effects of both common and uncommon genetic variants on these target proteins. The current review article provides a roadmap that investigators can utilize to determine the potential interactions between a patient's genotype, their phenotype, and their response to therapeutic interventions with both gene delivery and small molecules. Nonstandard Abbreviations and Acronyms ACMG American College of Medical Genetics and Genomics B/LB benign/likely benign BAG3 Bcl‐2–associated athanogene 3 CAPZB capping actin protein of muscle Z‐line subunit beta DCM dilated cardiomyopathy eQTL expression quantitative trait locus gnomAD Genome Aggregation Database GTEx Genotype‐Tissue Expression Hsc70 heat shock cognate Hsp70 70 kilo‐dalton heat shock protein IPV Ile‐Pro‐Val LAMP‐2 lysosomal associated membrane protein 2 LTCC L‐type voltage‐gated calcium channel Cav1.2 LD linkage disequilibrium NF‐κB nuclear factor kappa B P/LP pathogenic/likely pathogenic PDZGEF2 PDZ domain containing guanine nucleotide exchange factor 2 PPCM peripartum cardiomyopathy PXXP proline‐rich repeat SH3 Src homology 3 sHsps small heat shock proteins SIFT Sorting Intolerant From Tolerant VUS variant of uncertain significance Cardiomyopathies are a heterogeneous group of diseases of cardiac muscle 1 that include dilated, hypertrophic, restrictive, constrictive and arrhythmogenic right ventricular cardiomyopathies. 2 Dilated cardiomyopathies (DCMs) have been historically separated into those that are secondary to ischemic heart disease (ischemic DCM) and those that are nonischemic, with ischemic DCM being somewhat more common. Genetic variants were first shown to be etiologic in the development of hypertrophic cardiomyopathy 3 , 4 and novel therapies have been developed, using gene therapy 5 or small molecules. 6 By contrast, the cause of DCM has remained more obscure. Recent studies have shown convincingly that both heritable and sporadic genetic variants play a -Abstract Truncated-

A novel BAG5 variant impairs the ER stress response pathway, causing dilated cardiomyopathy and arrhythmia

Association Between SCN5A R225Q Variant and Dilated Cardiomyopathy: Potential Role of Intracellular Ph and WNT/β-catenin Pathway

GATA5 Loss-of-function Mutation in Familial Dilated Cardiomyopathy.

A Novel Nkx2-5 Loss-Of-Function Mutation Predisposes to Familial Dilated Cardiomyopathy and Arrhythmias

Genetics of BAG3: A Paradigm for Developing Precision Therapies for Dilated Cardiomyopathies

A Novel GATA4 Loss-of-function Mutation Responsible for Familial Dilated Cardiomyopathy

TBX5 Loss-of-function Mutation Contributes to Familial Dilated Cardiomyopathy

Identification of a LMNA (c.646c > T) Variant by Whole-Exome Sequencing in Combination with a Dilated Cardiomyopathy (DCM) Related Gene Filter in a Family with Familiar DCM

Impaired Cardiomyocyte Maturation Leading to DCM: A Case Report and Literature Review.

Overexpression of human BAG3P209L in mice causes restrictive cardiomyopathy

Detection and functional characterization of a novel <i>MEF2A</i> variation responsible for familial dilated cardiomyopathy

HAND1 loss-of-function mutation associated with familial dilated cardiomyopathy.

GATA4 Loss-of-function Mutation Underlies Familial Dilated Cardiomyopathy.

Gata6 Loss-Of-Function Mutations Contribute To Familial Dilated Cardiomyopathy

Novel familial dilated cardiomyopathy mutation in MYL2 affects the structure and function of myosin regulatory light chain

The Trans KCNMA1-M744T and Cis ANXA11-I457V and DYDC2-P123R Variants Are Associated with Familial Dilated Cardiomyopathy

Unraveling the pathogenesis of novel ANKRD1 missense mutation causing familial dilated cardiomyopathy using human-induced pluripotent stem cells derived cardiomyocytes

Dilated cardiomyopathy due to a novel combination of TTN and BAG3 genetic variants: From acute heart failure to subclinical phenotypes

ZBTB17 Loss-of-function Mutation Contributes to Familial Dilated Cardiomyopathy

VEZF1 Loss-of-function Mutation Underlying Familial Dilated Cardiomyopathy.

A potential pathogenic mutation of LAMA4 in a Chinese family with dilated cardiomyopathy and conduction system disease